Fianlimab
Fianlimab is Regeneron's LAG-3 blocker. Promising early data with cemiplimab did not hold up against pembrolizumab in a first-line phase 3 in 2026.
Phase 1 with cemiplimab reported ORR ~60% in first-line melanoma, prompting phase 3 trials versus pembrolizumab in metastatic disease (missed PFS, 2026) and in the adjuvant setting (ongoing). Also being tested in NSCLC. The result narrows the LAG-3 story to the specific nivolumab-relatlimab pairing so far.
1.Blocks LAG-3 on exhausted T cells
Compare all products across the US, EU, UK, Japan, China and Australia →
- 2026DesignationUS
First-line metastatic phase 3 missed its primary PFS endpoint (Regeneron release)
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Fianlimab" OR ABSTRACT:"Fianlimab" OR TITLE:"REGN3767" OR ABSTRACT:"REGN3767") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Fianlimab, not a curated reading list.